28
Participants
Start Date
November 30, 2011
Primary Completion Date
November 30, 2013
Study Completion Date
November 30, 2013
PD-0360324
Subjects will receive PD-0360324 intravenously in 3 different cohorts. The cohorts will be evaluated in ascending fashion. The doses planned are 100 mg every other week for 3 months, 150 mg every other week for 3 months, and 200 mg every 4 weeks for 3 months.
Placebo
Placebo is normal saline. The timing of placebo administration will depend of the dosing frequency of the cohort (either every other week for 3 months or every 4 weeks for 3 months).
Pfizer Investigational Site, Chisinau
Pfizer Investigational Site, Ducansville
Pfizer Investigational Site, Philadelphia
Pfizer Investigational Site, Wyomissing
Pfizer Investigational Site, Norfolk
Pfizer Investigational Site, Clarksburg
Pfizer Investigational Site, Charlotte
Pfizer Investigational Site, Orange Park
Pfizer Investigational Site, Oxford
Pfizer Investigational Site, Anniston
Pfizer Investigational Site, Jackson
Pfizer Investigational Site, Indianapolis
Pfizer Investigational Site, Fort Gratiot
Pfizer Investigational Site, Rapid City
Pfizer Investigational Site, Rapid City
Pfizer Investigational Site, Chicago
Pfizer Investigational Site, Dallas
Pfizer Investigational Site, Los Angeles
Pfizer Investigational Site, Markham
Lead Sponsor
Pfizer
INDUSTRY